Study aim: Evaluating the effectiveness of topiramate and lacosamide combination therapy in improving migraine headaches Design: A clinical trial with control group and parallel group design, phase 3 on 74 patients. Randomization will be done using random number table (permuted block method using blocks of size 4). Settings and conduct: Place of study: Ibn Sina Clinic, Sari, Mazandaran province; Study population: patients who have been diagnosed with chronic migraine based on ICHD-3 beta criteria and who includes inclusion criteria and do not have the exclusion criteria; Blinding type: double blind Participants/Inclusion and exclusion criteria: Inclusion Criteria: Adults over 18 years old with migraine (with aura or without aura) with a complaint of moderate to high intensity migraine headache (VAS≥4); Non-inclusion criteria; Severe depression or suicidal thoughts; Thyroid disorders; pregnancy or lactation; History of ischemic cerebral disease or ischemic heart disease; Renal dysfunction (GFR less than 30 ml/min); medication overuse headache Intervention groups: Intervention group: In the first week, all patients will receive lacosamide 100 mg twice a day, and from the second week, they will also receive 150 mg every 12 hours, and in the third week, 200 mg twice a day, if they tolerate, and they will also receive topiramate 25 mg once a day in the first week and after that 25 mg twice a day. Control group: all patients will receive placebo with the same shape and color as lacosamide twice a day, and they will also receive topiramate 25 mg once a day in the first week and after that 25 mg twice a day. Main outcome variables: The number of days a person experiences headache; the number of headache attacks